(19)
(11) EP 3 752 144 A1

(12)

(43) Date of publication:
23.12.2020 Bulletin 2020/52

(21) Application number: 19754182.4

(22) Date of filing: 11.02.2019
(51) International Patent Classification (IPC): 
A61K 31/395(2006.01)
A61K 31/5365(2006.01)
C07D 471/12(2006.01)
A61K 31/53(2006.01)
C07D 471/02(2006.01)
C07D 471/16(2006.01)
(86) International application number:
PCT/US2019/017409
(87) International publication number:
WO 2019/160783 (22.08.2019 Gazette 2019/34)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 15.02.2018 US 201862630974 P

(71) Applicant: Merck Sharp & Dohme Corp.
Rahway, New Jersey 07065-0907 (US)

(72) Inventors:
  • EMBREY, Mark, W.
    West Point, Pennsylvania 19486 (US)
  • HARTINGH, Timothy John
    West Point, Pennsylvania 19486 (US)
  • LABROLI, Marc
    West Point, Pennsylvania 19486 (US)
  • RAHEEM, Izzat, T.
    West Point, Pennsylvania 19486 (US)

(74) Representative: Jaap, David Robert 
MSD Hertford Road
Hoddesdon, Herts EN11 9BU
Hoddesdon, Herts EN11 9BU (GB)

   


(54) TRICYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS